Anti-Human Endosialin/CD248 Reference Antibody (Ontuxizumab, RUO) (HV681016)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HV681016
Description	Ontuxizumab (HV681016) is a research-grade recombinant antibody targeting CD164L. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Humanized
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	Endosialin, TEM1, CD164L1, Tumor endothelial marker 1, CD248
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q9HCU0
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	MORAb-004, 946415-62-9
Background	Endosialin (CD248) is a ~80 kDa protein. Cell surface glycoprotein involved in various biological processes including angiogenesis, immune response modulation, and tissue remodeling and repair. Participates in pericyte proliferation through positive modulation of the PDGF receptor signaling pathway. Acts as a scaffold for factor X, triggering allosteric changes and the spatial re-alignment of factor X with the TF-factor VIIa complex, thereby enhancing coagulation activation. Modulates the insulin signaling pathway by interacting with insulin receptor/INSR and by diminishing its capacity to be autophosphorylated in response to insulin. Also regulates LPS-induced inflammatory response in macrophages by favoring the production of proinflammatory cytokines. 1. Tomkowicz, B. et al. (2010) Cancer biology & therapy 9, 908-15. PMID: 20484976 2. Hardie, DL. et al. (2011) Immunology 133, 288-95. PMID: 21466550
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

SEC-HPLC detection for Research Grade Ontuxizumab.
SDS-PAGE

SDS-PAGE for Research Grade Ontuxizumab

References

Datasheet

Anti-Human Endosialin/CD248 Reference Antibody (Ontuxizumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Human Endosialin/CD248 Reference Antibody (Ontuxizumab, RUO) (HV681016)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us